Differences in osteogenic and apoptotic genes between osteoporotic and osteoarthritic patients

BMC Musculoskeletal Disorders

Ramón Pérez-Cano¹  Cristina Miranda²  Mª José Montoya¹  Mercè Giner¹ 

[1]Medicine Department, University of Seville, Seville, Spain

[2]Bone Metabolism Unit, Internal Medicine, “Virgen Macarena” University Hospital, Avda. Dr. Fedriani s/n, 41009, Sevilla, SPAIN

关键词: Microstructural;    Apoptosis;    Osteogenesis;    Osteoporosis;    Human bone;   

Others  :  1134098
DOI  :  10.1186/1471-2474-14-41

 received in 2012-06-19, accepted in 2013-01-22,  发布年份 2013

【 摘 要 】

Background

Osteoporosis is a metabolic disorder characterized by a reduction in bone mass and deterioration in the microarchitectural structure of the bone, leading to a higher risk for spontaneous and fragility fractures.

The main aim was to study the differences between human bone from osteoporotic and osteoarthritic patients about gene expression (osteogenesis and apoptosis), bone mineral density, microstructural and biomechanic parameters.

Methods

We analyzed data from 12 subjects: 6 with osteoporotic hip fracture (OP) and 6 with hip osteoarthritis (OA), as the control group. All subjects underwent medical history, analytical determinations, densitometry, histomorphometric and biochemical study. The expression of 86 genes of osteogenesis and 86 genes of apoptosis was studied in pool of bone samples from patients with OP and OA by PCR array.

Results

We observed that most of the genes of apoptosis and osteogenesis show a decrease in gene expression in the osteoporotic group in comparison with the osteoarthritic group. The histomorphometric study shows a lower bone quality in the group of patients with hip fractures compared to the osteoarthritic group.

Conclusions

The bone tissue of osteoporotic fracture patients is more fragile than the bone of OA patients. Our results showed an osteoporotic bone with a lower capacities for differentiation and osteoblastic activity as well as a lower rate of apoptosis than osteoarthritic bone. These results are related with structural and biochemical parameters.

【 授权许可】

   
2013 Giner et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Rachner TD, Khosla S, Hofbauer LC: Osteoporosis: now and the future. Lancet 2011, 377(9773):1276-1287.
• [2]Jemtland R, Holden M, Reppe S, Olstad OK, Reinholt FP, Gautvik VT, Refvem H, Frigessi A, Houston B, Gautvik KM: Molecular disease map of bone characterizing the postmenopausal osteoporosis phenotype. J Bone Miner Res 2011, 26(8):1793-1801.
• [3]Javed A, Chen H, Ghori FY: Genetic and transcriptional control of bone formation. Oral Maxillofac Surg Clin North Am 2010, 22(3):283-293.
• [4]Velasco J, Zarrabeitia MT, Prieto JR, Perez-Castrillon JL, Perez-Aguilar MD, Perez-Nuñez MI, Sañudo C, Hernandez-Elena J, Calvo I, Ortiz F, Gonzalez-Macias J, Riancho JA: Wnt pathway genes in osteoporosis and osteoarthritis: differential expression and genetic association study. Osteoporos Int 2010, 21(1):109-118.
• [5]Zelzer E, Olsen BR: Multiple roles of vascular endothelial growth factor (VEGF) in skeletal development, growth, and repair. Curr Top Dev Biol 2005, 65:169-187.
• [6]Kim SJ, Kim SY, Kwon CH: Differential effect of FGF and PDGF on cell proliferation and migration in osteoblastic cells. Growth Factors 2007, 25(2):77-86.
• [7]Kearns AE, Khosla S, Kostenuik PJ: Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr Rev 2008, 29(2):155-192.
• [8]Hock JM, Krishnan V, Onyia JE, Bidwell JP, Milas J, Stanislaus D: Osteoblast apoptosis and bone turnover. J Bone Miner Res 2001, 16(6):975-984.
• [9]Moriishi T, Maruyama Z, Fukuyama R, Ito M, Miyazaki T, Kitaura H, Ohnishi H, Furuichi T, Kawai Y, Masuyama R, Komori H, Takada K, Kawaguchi H, Komori T: Overexpression of Bcl2 in osteoblasts inhibits osteoblast differentiation and induces osteocyte apoptosis. PLoS One 2011, 6(11):e27487.
• [10]Cano A, Dapía S, Noguera I: Comparative effects of 17beta-estradiol, raloxifene and genistein on bone 3D microarchitecture and volumetric bone mineral density in the ovariectomized mice. Osteoporos Int 2008, 19(6):793-800.
• [11]Wang B, Wood IS, Trayhurn P: PCR arrays identify metallothionein-3 as a highly hypoxia-inducible gene in human adipocytes. Biochem Biophys Res Commun 2008, 368(1):88-93.
• [12]Hopwood B, Tsykin A, Findlay DM, Fazzalari NL: Gene expression profile of the bone microenvironment in human fragility fracture bone. Bone 2009, 44(1):87-101.
• [13]Dragojevič J, Logar DB, Komadina R, Marc J: Osteoblastogenesis and adipogenesis are higher in osteoarthritic than in osteoporotic bone tissue. Arch Med Res 2011, 42(5):392-397.
• [14]Napal J, Amado JA, Riancho JA, Olmos JM, González-Macías J: Stress decreasesthe serum level of osteocalcin. Bone Miner 1993, 21(2):113-118.
• [15]Kumarasinghe DD, Hopwood B, Kuliwaba JS, Atkins GJ, Fazzalari NL: An update on primary hip osteoarthritis including altered Wnt and TGF-β associated gene expression from the bony component of the disease. Rheumatology (Oxford) 2011, 50(12):2166-2175.
• [16]Kumarasinghe DD, Perilli E, Tsangari H, Truong L, Kuliwaba JS, Hopwood B, Atkins GJ, Fazzalari NL: Critical molecular regulators, histomorphometric indices and their correlations in the trabecular bone in primary hip osteoarthritis. Osteoarthr Cartil 2010, 18(10):1337-1344.
• [17]Kaji H, Naito J, Sowa H: Smad3 differently affects osteoblast differentiation depending upon its differentiation stage. Horm Metab Res 2006, 38(11):740-745.
• [18]Cunningham NS, Paralkar V, Reddi AH: Osteogenin and recombinant bone morphogenetic protein 2B are chemotactic for human monocytes and stimulate transforming growth factor beta 1 mRNA expression. Proc Natl Acad Sci USA 1992, 89(24):11740-11744.
• [19]Zhu F, Friedman MS, Luo W: The transcription factor osterix (SP7) regulates BMP6-induced human osteoblast differentiation. J Cell Physiol 2012, 227(6):2677-2685.
• [20]Snelling SJB, Hulley PA, Loughlin J: BMP5 activates multiple signaling pathways and promotes chondrogenic differentiation in the ATDC5 growth plate model. Growth Factors 2010, 28(4):268-279.
• [21]García S, Forteza J, López-Otin C: Matrix metalloproteinase-8 deficiency increases joint inflammation and bone erosion in the K/BxN serum-transfer arthritis model. Arthritis Res Ther 2010, 12(6):R224. BioMed Central Full Text
• [22]Zupan J, Komadina R, Marc J: The relationship between osteoclastogenic and anti-osteoclastogenic pro-inflammatory cytokines differs in human osteoporotic and osteoarthritic bone tissues. J Biomed Sci 2012, 1:19-28.
• [23]Zhu J, Shimizu E, Zhang X: EGFR signaling suppresses osteoblast differentiation and inhibits expression of master osteoblastic transcription factors Runx2 and Osterix. J Cell Biochem 2011, 112(7):1749-1760.
• [24]Feito MJ, Lozano RM, Alcaide M: Immobilization and bioactivity evaluation of FGF-1 and FGF-2 on powdered silicon-doped hydroxyapatite and their scaffolds for bone tissue engineering. J Mater Sci Mater Med 2011, 22(2):405-416.
• [25]Dunstan CR, Boyce R, Boyce BF: Systemic administration of acidic fibroblast growth factor (FGF-1) prevents bone loss and increases new bone formation in ovariectomized rats. J Bone Miner Res 1999, 14(6):953-959.
• [26]Wang W, Li S, Niu D: Study on relationship between osteoporosis and mRNA expressions of vascular endothelial growth factor and bone morphogenetic protein 2 in nontraumatic avascular necrosis of femoral head. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi 2010, 24(9):1072-1077.
• [27]Schultz DR, Harrington WJ Jr: Apoptosis: programmed cell death at a molecular level. Semin Arthritis Rheum 2003, 32(6):345-369.
• [28]van Kooten C, Banchereau J: CD40-CD40 ligand. J Leukoc Biol 2000, 67(1):2-17.
• [29]Blagosklonny MV: Cell death beyond apoptosis. Leukemia 2000, 14(8):1502-1508.
• [30]Bran GM, Stern-Straeter J, Hörmann K: Apoptosis in bone for tissue engineering. Arch Med Res 2008, 39(5):467-482.
• [31]Chipuk JE, Moldoveanu T, Llambi F: The BCL-2 family reunion. Mol Cell 2010, 37(3):299-310.
• [32]Delgado-Calle J, Arozamena J, García-Renedo R, García-Ibarbia C, Pascual-Carra MA, González-Macías J, Riancho JA: Osteocyte deficiency in hip fractures. Calcif Tissue Int 2011, 89(4):327-334.
• [33]Hofbauer LC, Gori F, Riggs BL: Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis. Endocrinology 1999, 140(10):4382-4389.
• [34]Weinstein RS, O’Brien CA, Almeida M: Osteoprotegerin prevents glucocorticoid-induced osteocyte apoptosis in mice. Endocrinology 2011, 152(9):3323-3331.
• [35]Shen Y, Zhang Z-M, Jiang S-D: Postmenopausal women with osteoarthritis and osteoporosis show different ultrastructural characteristics of trabecular bone of the femoral head. BMC Musculoskelet Disord 2009, 10:35. BioMed Central Full Text
• [36]Patsch JM, Kohler T, Berzlanovich A: Trabecular bone microstructure and local gene expression in iliac crest biopsies of men with idiopathic osteoporosis. J Bone Miner Res 2011, 26(7):1584-1592.